Skip to main
ALZN

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company dedicated to creating novel treatments for neurodegenerative diseases and psychiatric disorders, with a specific focus on Alzheimer's disease. The company has reported positive top-line results from its studies in June 2023, signifying potential advancements in its drug pipeline, which includes innovative therapies such as AL001 and AL002. With an attractive current valuation, as highlighted by a net present value (NPV) analysis, the company presents significant upside potential, driven by the achievement of key milestones and the continuation of favorable data outcomes.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), significantly worse than estimates of $(0.69). The company faces numerous threats to its financial success, including balance sheet and liquidity risks, potential failures in demonstrating safety and efficacy of its drug candidates, and challenges in obtaining regulatory approvals. Additionally, competitive pressures and shifting investor sentiment towards biotech stocks may further hinder Alzamend Neuro's growth prospects and overall market performance.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.